Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-11-20
2007-11-20
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S254080, C514S323000, C548S420000, C546S200000, C544S372000
Reexamination Certificate
active
10518624
ABSTRACT:
The present invention relates to novel tetracyclic arylalkyl indoles, their derivatives, their analogues, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, novel intermediates described herein and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel tetracyclic arylalkyl of the general formula (I), their derivatives, their analogues, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, novel intermediates described herein and pharmaceutically acceptable compositions containing them. This invention also relates to process/es for preparing such compound/s of general formula (I), composition/s containing effective amount/s of such a compound and the use of such a compound/composition in therapy.
REFERENCES:
patent: 4839377 (1989-06-01), Bays et al.
patent: 4855314 (1989-08-01), Oxford et al.
patent: 303506 (1989-02-01), None
patent: 313397 (1989-04-01), None
patent: 354777 (1991-02-01), None
patent: 438230 (1991-07-01), None
patent: 457701 (1991-11-01), None
patent: 497512 (1992-08-01), None
patent: 2035310 (1980-06-01), None
patent: 91/18897 (1991-12-01), None
patent: 93/00086 (1993-01-01), None
patent: 93/23396 (1993-11-01), None
patent: 94/06769 (1994-03-01), None
Morissette et al. Advanced Drug Delivery Reviews 2004, 56, 275-300.
Kozikowski et al. Tetrahedron Lett. 1991, 32(28), 3317-20.
Barnes et al. Neuropharmacology 1999, 38, 1083-1152.
Bassiony et al. Psychosomatics 2003, 44(5), 388-401.
Gershon, M. D. Ailment Pharmacol. Ther. 2004, 20(suppl. 7), 3-14.
Fuller, R.W., Drugs Acting on Serotonergic Neuronal Systems, Biology of Serotonergic Transmission, John Wiley & Sons Ltd. (1982), 221-247.
Gershon M.D. et al., The periphal actions of 5-Hydroxytryptamine (1989), 246.
Saxena P.R. et al., Journal of Cardiovascular Pharmacology (1990), supplement 7,15.
Glennon et al., Neuroscience and Behavioral Reviews (1990), 14, 35.
Hoyer D. et al., Pharmacol. Rev. (1994), 46, 157-203.
Ruat M. et al., Biochem. Biophys. Res. Com. (1993), 193, 269-276.
Roth et al., J. Pharm. Exp. Therapeut. (1994), 268, 1403-1410.
Sleight et al., Exp. Opin Ther. Patents (1998), 8, 1217-1224.
Bourson et al, Brit J. Pharmacol. (1998), 125, 1562-1566.
Boess et al, Mol. Pharmacol., 1998, 54, 577-583.
Sleight et al., Brit J. Pharmacol. (1998), 124, 556-562.
Yoshioka et al, Life Sciences (1998), 17/18, 1473-1477.
Schoeffter P. et al. “SDZ216-525, a selective and potent 5-HT1A receptor antagonist” European Journal of Pharmacology, 224, 251-257 (1993).
Battula Srinivasa Reddy
Jasti Venkateswarlu
Kambhampati Rama Sastri
Ramakrishna Venkata Satya Nirogi
Rao Venkata Satya Veerabhadra Vadlamudi
Darby & Darby
Nolan Jason M.
Saeed Kamal A.
Suven Life Sciences Limited
LandOfFree
Arylalkyl indoles having serotonin receptor affinity useful... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arylalkyl indoles having serotonin receptor affinity useful..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylalkyl indoles having serotonin receptor affinity useful... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3855313